Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

Status Recruiting

Clinical Trial Summary

A study of sevasemten (EDG-5506) in Becker muscular dystrophy (known as CANYON) and pivotal cohort (known as GRAND CANYON). The EDG-5506-201 CANYON study was expanded to include an additional 120 adult participants in a cohort called GRAND CANYON, that is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of sevasemten in adults with Becker. CANYON is fully enrolled; GRAND CANYON is currently enrolling.

Clinical Trial Description

The EDG-5506-201 protocol was amended to include an additional cohort thus consists of two parts. Part 1: CANYON is a double-blind, randomized, placebo-controlled design to investigate the effect of sevasemten on the safety, pharmacokinetics, biomarkers, and functional measures. Approximately 32 adults and 18 adolescents with Becker muscular dystrophy are planned to enroll in this study. This study will have up to a 4-week Screening period, a 12-month Treatment period, followed by a 4-week follow-up period. Approximately 32 adult participants will randomize to Cohort 1 or Cohort 2 in a 1:1 ratio then each cohort will further randomize to sevasemten or placebo in a 3:1 ratio. Approximately 9 adolescent participants will enroll in Cohort 4 and randomize in a 2:1 ratio to sevasemten or placebo. Cohort 5 will randomize an additional 9 participants in a 2:1 ratio to either sevasemten or placebo after Cohort 4. CANYON is now fully enrolled. Part 2: GRAND CANYON or Cohort 6 is a double-blind, randomized, placebo-controlled design to investigate the safety and efficacy of sevasemten in adults with Becker muscular dystrophy after 18 months of treatment. Approximately 120 adults with Becker muscular dystrophy are planned to enroll in this study. This study will have up to a 4-week Screening period, an 18-month Treatment period, followed by a 4-week follow-up period. Approximately 120 adult participants will be randomized in Cohort 6 in a 2:1 ratio either to sevasemten or placebo. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05291091
Study type	Interventional
Source	Edgewise Therapeutics, Inc.
Contact	Edgewise Therapeutics
Phone	720-262-7002
Email	studies@edgewisetx.com
Status	Recruiting
Phase	Phase 2
Start date	July 6, 2022
Completion date	June 2026

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01168908` - Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy	Phase 2
Recruiting	`NCT01484678` - Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
Completed	`NCT02847975` - Sodium Nitrate to Improve Blood Flow	Phase 1
Completed	`NCT02147639` - Effects of Sodium Nitrate on Blood Flow in Becker Muscular Dystrophy	Phase 2/Phase 3
Recruiting	`NCT02069756` - The Duchenne Registry
Completed	`NCT04585464` - A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults	Phase 1
Recruiting	`NCT04668716` - Brain Involvement in Dystrophinopathies Part 2
Completed	`NCT03236662` - (-)- Epicatechin Becker Muscular Dystrophy	Phase 2
Completed	`NCT01350154` - Effect of Modulating the nNOS System on Cardiac, Muscular and Cognitive Function in Becker Muscular Dystrophy Patients	Phase 2
Enrolling by invitation	`NCT06066580` - Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy	Phase 2
Not yet recruiting	`NCT06363526` - Effectiveness of 5-week Digital Respiratory Practice in a Group of Children With Duchenne Muscular Dystrophy and Becker Muscular Dystrophy.	N/A
Recruiting	`NCT05409079` - Schulze Muscular Dystrophy Ability Clinical Study	N/A
Completed	`NCT01856868` - Use of (-)-Epicatechin in the Treatment of Becker Muscular Dystrophy (Pilot Study)	Phase 1/Phase 2
Completed	`NCT01557400` - Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and Canada	Phase 3
Recruiting	`NCT02109692` - Evaluation of Muscle miRNA as Biomarkers in Dystrophinopathies	N/A
Recruiting	`NCT03057002` - UTSW HP [13-C] Pyruvate Injection in HCM
Recruiting	`NCT04583917` - Brain Involvement in Dystrophinopathies Part 1
Withdrawn	`NCT03076814` - Functional Muscle Ischemia With Tadalafil Treatment in Becker Muscular Dystrophy	N/A
Completed	`NCT02207283` - PDE5 Inhibition to Alleviate Functional Muscle Ischemia in Becker Muscular Dystrophy	Phase 4
Completed	`NCT00873782` - Safety Study of Transvenous Limb Perfusion in Human Muscular Dystrophy	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.